Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy for medulloblastoma.

Nicholas G Gottardo1, Amar Gajjar

  • 1Division of Neuro-oncology, Department of Hematology-Oncology, St. Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA.

Current Treatment Options in Neurology
|September 1, 2006
PubMed
Summary

Medulloblastoma survival has improved, but challenges remain for metastatic disease and treatment toxicity. Molecular profiling promises better risk stratification and personalized therapies for improved outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paediatric therapeutic development workshop on medulloblastoma.

British journal of cancer·2026
Same author

Surgical resection in medulloblastoma: a crossroads in the molecular era.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2026
Same author

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

EClinicalMedicine·2026
Same author

Neoadjuvant chemotherapy for pineal region tumors.

Journal of neuro-oncology·2026
Same author

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

The Lancet. Child & adolescent health·2026
Same author

From favourable to fatal: survival outcomes among young children with non-WNT/non-SHH medulloblastoma.

The Lancet. Child & adolescent health·2026

Area of Science:

  • Pediatric Oncology
  • Neuro-Oncology
  • Cancer Molecular Biology

Background:

  • Medulloblastoma treatment has advanced, improving survival rates with multimodal therapy.
  • Current therapies achieve 75-80% progression-free survival (PFS) in average-risk and 60% in high-risk patients.
  • Significant challenges persist, including poor outcomes for metastatic disease (M2/M3) and treatment-related toxicities.

Purpose of the Study:

  • To highlight the need for improved medulloblastoma patient stratification.
  • To emphasize the potential of molecular alterations in refining treatment strategies.
  • To advocate for personalized therapies to reduce toxicity and improve outcomes.

Main Methods:

  • Review of current medulloblastoma treatment protocols and outcomes.

Related Experiment Videos

  • Analysis of existing data on molecular alterations and their prognostic significance.
  • Discussion of the potential of targeted therapies based on tumor biology.

    • Main Results:

    • Despite advances, metastatic medulloblastoma (M2/M3) has a poor PFS (up to 40%).
    • Overtreatment occurs in some patients, leading to unnecessary long-term neurocognitive and neuroendocrine toxicities.
    • Identified molecular alterations suggest prognostic significance and therapeutic targets.

    Conclusions:

    • Accurate patient stratification is crucial for optimizing medulloblastoma treatment.
    • Integrating molecular profiles with clinical variables will enable individualized therapy.
    • Targeted therapies hold promise for improving outcomes and reducing toxicity in medulloblastoma patients.